entertainment -WSS

entertainment

author：entertainment 2025-10-03 01:03:36 - browse：9

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why are Kaiser Permanente staff considering a strike?

WSS

Maui wildfire now ranks as the fifth

Experts study whether long Covid risk adds up with each reinfection

Why are Kaiser Permanente staff considering a strike?

Biotech lab space demand falls sharply

It's been 20 years since Dolly the sheep. Where's my clone?

It's been 20 years since Dolly the sheep. Where's my clone?

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

Experts study whether long Covid risk adds up with each reinfection

Novavax promises a turnaround & Lilly roils the obesity market

Illinois Supreme Court finds assault weapons ban constitutional

Psychedelics group wrestles with new pharma identity

How Vertex's cystic fibrosis drug is changing patients' lives

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Montana youths win climate lawsuit against state for promoting fossil fuels

Medicare proposal to cover medical devices draws a mixed reaction

Patients, digital health players weigh in on FTC's data privacy plan

Wikipedia

Megan Rapinoe shares emotional post following US Women's World Cup exit

Lasker Awards 2023: Winners in biomedical research

Maui wildfire now ranks as the fifth

Illumina slashes 2023 revenue projections yet again

It's been 20 years since Dolly the sheep. Where's my clone?

Biden administration begins canceling student loan debt for 804,000 borrowers

knowledge

hotspot

entertainment

focus